Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 13;11(1):2025668. doi: 10.1080/2162402X.2022.2025668

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 2. — TCR diversity associated with treatment outcome of radiotherapy combined with camrelizumab.

(a) Responsive patients had lower clonality in baseline tumors. (b) Responsive patients had higher Shannon index, lower clonality and lower Simpson’s index in peripheral CD8⁺ T cells during treatment. (c and d) Landmark analysis of overall survival and progression-free survival among patients in TCR Shannon index (c) and clonality (d) of baseline peripheral CD8⁺ T cells. Responsive: partial + completed response. Non-responsive: stable + progressive disease. BLT, baseline tumor tissues. RTC, peripheral CD8⁺ T cells after 40 Gy radiation and 2 rounds of camrelizumab. BLC, baseline peripheral CD8⁺ T cells. Black solid line, landmark point. P < .05, significant difference.